Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
Despite a meteoric long-term rise, D-Wave Quantum's recent sharp decline highlights the extreme risks and towering valuations inherent in the speculative quantum computing sector. Investors face a critical decision.
While the FTSE 100 grapples with global headwinds, a segment of smaller UK-listed companies presents distinct opportunities. We examine three firms, each with a market capitalisation over £90 million, that combine financial resilience with specific growth catalysts.
As the FTSE 100 hits record highs, a broader rally in UK mid and small-cap indices is prompting a strategic rethink. Analysts debate whether these long-neglected shares, now showing historic undervaluation, are poised for a major comeback.
Shares of insulin pump maker Tandem Diabetes Care have plummeted over 80% in five years, trading near $20. A deep dive into valuation metrics suggests the stock may now be modestly undervalued, but significant risks and competitive pressures remain.
Backed by a major U.S. government loan and a surge in private equity, USA Rare Earth is accelerating its domestic mining and manufacturing projects, positioning itself at the forefront of a critical national strategy.
ProPublica has identified the two Customs and Border Protection officers who discharged their weapons during an encounter that resulted in the death of Alex Pretti, a 37-year-old nurse. The incident has intensified scrutiny of federal immigration enforcement tactics in urban areas.
As confidence in the Eurozone's recovery builds, investors are scrutinizing companies where executives hold significant equity stakes—a potential signal of alignment and long-term conviction. We spotlight three firms from a broader screen of 220 high-insider-ownership growth stocks.
Amidst a complex global economic backdrop, Asia's equity markets are hiding gems trading significantly below their estimated intrinsic value. We spotlight three companies—from gaming to aviation and medtech—that our cash flow analysis suggests are deeply discounted, offering potential for investors with an eye on long-term fundamentals.
Columbia Financial (CLBK) announces a major executive reshuffle, promoting its long-time CFO to Chief Banking Officer and appointing a new finance chief. The move comes as the stock shows recent gains but longer-term weakness, raising questions about its current valuation and future trajectory.
As the ASX braces for a turbulent week amid rate hike fears, investors are scouring the market for resilient opportunities. We delve into three penny stocks—spanning energy, retail, and healthcare—that combine financial stability with distinct growth narratives for the discerning investor.
As a partial government shutdown enters its third day, Rep. Ro Khanna (D-Calif.) is rallying House Democrats to reject a reopening bill, arguing it would endorse controversial ICE tactics. The standoff centers on separating Homeland Security funding from other agencies.
The collapse of Shenzhen-based Jereh, a gold trading platform that operated with massive leverage and no physical backing, has left a trail of financial devastation for 150,000 retail investors, who now confront a controversial repayment plan offering mere fractions of their investments.
Human remains believed to be those of 19-year-old Matthew Packard-Asai have been found off Kahili Beach, ending a days-long search after he was pulled into the ocean by strong surf.
The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
QuantumScape's stock has plummeted 52% in three months, reigniting the debate over its valuation. While bulls point to a disruptive solid-state battery technology and a theoretical fair value of $55, skeptics highlight the absence of revenue and monumental scaling challenges. We examine the risks and rewards behind the volatility.
In a major strategic shift, uranium-focused Energy Fuels announces a deal to acquire Australian Strategic Materials, aiming to create a vertically integrated rare earths producer outside China. The move comes as the company's stock, already on a meteoric rise, faces new questions about its growth trajectory and valuation.
Amidst a challenging macro landscape, telecom operator VEON Ltd. is posting robust growth in its core frontier markets while aggressively expanding its digital ecosystem. With a valuation significantly below peers, analysts are debating whether the market is overlooking a hidden gem or rightly pricing in geopolitical risks.
As gold and silver surge to record highs, Bitcoin's recent slump reignites debate over its viability as a modern safe-haven asset, challenging its long-touted 'digital gold' narrative.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
